News
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback